Screener
Halozyme Therapeutics HALO Invested capital
Discontinued — last reported Q2 '26
Invested capital at other companies
Other financials
Where this comes from
Calculated from Halozyme Therapeutics’s reported figures.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
FAQ
- What is Halozyme Therapeutics's invested capital?
- Halozyme Therapeutics (HALO) reported invested capital of $2.16B in Q2 2026.
- How has Halozyme Therapeutics's invested capital changed year-over-year?
- Halozyme Therapeutics's invested capital increased by 19.3% year-over-year, from $1.81B to $2.16B.
- What is the long-term trend for Halozyme Therapeutics's invested capital?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's invested capital has grown at a 38.8% compound annual growth rate (CAGR), from $404.94M to $2.09B.
- What does invested capital mean?
- Total debt plus shareholders' equity minus cash, at the quarter end. The capital actually put to work in the operating business — the denominator of return on invested capital (ROIC).
Ask your AI about Halozyme Therapeutics's invested capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude